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SLAMAbstract Background: Previous studies reported higher interleukin-6 (IL-6) levels in systemic
lupus erythematosus (SLE) patients than in healthy controls. However, the clinical relevance of
IL-6 in SLE has not been clearly established.
Aim of the work: The present study aimed to evaluate the clinical significance of serum and
urinary IL-6 and their usefulness as markers of disease activity in SLE.
Patients and methods: 63 SLE patients were included. Disease activity was assessed according to
the Systemic Lupus Activity Measure (SLAM) score. Serum and urinary IL-6 were assessed by
ELISA.
Results: The study included 63 Romanian patients, female to male ratio 9.5:1 with a mean age of
45.4 ± 12.6 years and disease duration of 8 (3–12.3) years. The median SLAM score at inclusion
was 5 (range 3–8). Urinary IL-6 significantly correlated with proteinuria (r= 0.25; p= 0.04) and
negatively with the platelet count, C3 and C4 levels (r= 0.38; p= 0.002, r= 0.43;
p= 0.001, and r= 0.46; p< 0.001 respectively). Moreover, in patients with active lupus nephri-
tis (LN), urinary IL-6 correlated with the SLAM (r= 0.62; p= 0.01). Patients with low urinary
IL-6 levels (<7.3 pg/ml) had a longer duration of treatment with corticosteroids or hydroxychloro-
quine (HCQ) (9.5 vs 4 years; p= 0.02 and 7 vs 4 years; p= 0.02). In a regression, only C3 was a
significant determinant of urinary IL-6 level.n Rheu-
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Treatment with corticosteroids or HCQ therapy might reduce urinary IL-6 levels in SLE.
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Interleukin-6 (IL-6) is not only an important cytokine in the
inflammation cascade [1], but has also pleiotropic functions
in the regulation of the immune system [2]. For instance,
IL-6 has pro-inflammatory properties as an important induc-
tor of acute phase proteins [3,4] and, on the other hand, is
involved in the anti-inflammatory responses [5,6].
Multiple studies have identified higher IL-6 levels in SLE
patients in different samples analyzed: serum [7–9], urine
[10,11], cerebrospinal [12] or bronchoalveolar lavage fluid
[13]. Regarding the urinary IL-6 expression, there are data sus-
taining a local, renal, IL-6 production in SLE patients with
active lupus nephritis (LN) [14,15]. However, the relationships
between IL-6 levels and SLE disease activity are unsettled.
Furthermore, IL-6 gene polymorphisms were reported in
SLE patients [16].
Nevertheless, IL-6 was proposed as a therapeutic target in
SLE [17]. Tocilizumab, an anti-IL-6 receptor antibody, ini-
tially used in patients with rheumatoid arthritis, was then tried
in SLE [18]. However, anti-IL-6 therapy has not shown signif-
icant benefits in SLE, even if it decreased the disease activity
and improved outcomes in SLE arthritis were noted [19].
Although a possible role of IL-6 as therapeutic target in SLE
seems now improbable and this approach could be probably
considered for future research only in selected patients, the
involvement of IL-6 in SLE’s pathogenesis cannot be denied
and understanding its role could help clarify the heterogenic
immunity of this disease.
The present study aimed to evaluate the usefulness of serum
and urinary IL-6 levels as markers of disease activity in SLE.2. Patients and methods
Sixty-three consecutive SLE patients fulfilling 2012 Systemic
Lupus International Collaborating Clinics (SLICC) SLE crite-
ria [20] were included in the study. Those with acute or chronic
infectious conditions, pregnancy, neoplasia or overlap with
another autoimmune disease were excluded. After patients
signed the informed consent, the same protocol was applied
to all. The study was approved by the ethics committee of
Colentina Clinical Hospital and conforms to the Helsinki
declaration.
Medical records were reviewed and complete laboratory
data were collected. Blood and urine samples were collected
at inclusion. In order to appreciate disease activity, the Sys-
temic Lupus Activity Measure (SLAM), a SLE activity score
[21] was computed at enrollment. SLAM scores several lupus
impairments, like constitutional, mucocutaneous, ocular, retic-
uloendothelial, cardiovascular, pulmonary, gastrointestinal,
neuromotor, and musculoskeletal. Renal involvement is evalu-
ated into SLAM score related to serum creatinine and urinary
sediment.l. Clinical significance of serum and urin
j.ejr.2016.05.005All clinical active involvements in SLE disease (i.e. cuta-
neous, joint, serositis) were defined according to 2012 SLICC
criteria [20]. In case of renal SLE involvement, data on urine
examination (urinary sediment and proteinuria in a 24 h col-
lection) as well as estimated glomerular filtration rate (Modifi-
cation of Diet in Renal Disease (MDRD) Study equation [22])
were available. LN was defined as proteinuria P500 mg/day
and/or hematuria [20].
2.1. Serum and urinary IL-6 measurements
Peripheral blood samples were centrifuged 15 min at 4000 rpm.
The biological samples were stored at 70. Serum and uri-
nary IL-6 levels were assessed by sandwich ELISA (DRG
International, Inc. USA) according to manufacturer’s instruc-
tions in the Immunology Laboratory of Colentina Research
Center. For each sample, mean optical density at 450 nm
was considered (BioRad Hercules, CA, USA).
2.2. Statistical analysis
The characteristics were summarized as mean and standard
deviation (SD) or as median (quartile 1; quartile 3), (q1; q3),
according to the distribution. Nominal data are presented as
percentages. Subgroups of patients were defined based on the
observed median urinary IL-6 (7.3 pg/ml), as reference data
are not available and based on the presence of renal involve-
ment, lupus nephritis (LN). Differences between subgroups
were evaluated by Chi-squared test for categorical variables,
T-independent test for normally distributed variables, and
Mann–Whitney test for the others. The non-parametric Spear-
man test (r= Spearman’s rho coefficient) was used to analyze
the bivariate correlations. Multivariate logistic regression
models were used to assess the determinants of the urinary
IL-6. Two-sided p-values < 0.05 were considered statistically
significant. For all analysis, SPSS (Chicago, IL, USA) was
used.
3. Results
The cohort consisted of 63 Romanian SLE patients, female to
male ratio 9.5:1 with a mean age at inclusion of 45.4
± 12.6 years. The median SLAM score at inclusion was 5
(range 3–8) (Table 1). The hematological manifestations were
the most frequent at inclusion (42.9%), followed by the artic-
ular (39.7%), cutaneous (34.9%) and renal (23.8%) ones. Most
of the patients were treated with corticosteroids (87.3%) and
hydroxychloroquine (HCQ) (71.4%) for a median period of
6 years.
Serum IL-6 was not related to any of the investigated
parameters (data not shown). Moreover, serum and urinary
IL-6 levels were not correlated (r= 0.02; p= 0.09). In the
whole cohort, urinary IL-6 was correlated with some indicesary interleukin-6 in systemic lupus erythematosus patients, The Egyptian Rheu-
Table 1 Demographic features, renal involvement, laboratory investigations, disease activity and medications received by systemic
lupus erythematosus patients according to those with low and high urinary IL-6 levels.
Variable All (n= 63) Urinary IL-6 (pg/ml) p
Low (n= 33) High (n= 30)
Demographic
F:M 57:6 29:4 28:2 0.4
Age (years) 45.4 ± 12.6 48.0 ± 11.5 43.3 ± 13.6 0.3
DD (years) 8 (3–12.3) 10 (5.5–14.5) 6.0 (1.0–11.0) 0.04
Lab. investigations
TLC (103/ml) 6.8 (5.1–10.6) 7.1 (5.2–10.2) 6.7 (5–10.7) 0.8
LYM (103/ml) 1.6 (1.2–2.2) 1.7 (1.2–2.3) 1.5 (1.1–2.2) 0.4
Hb (g/dl) 12.4 ± 2.1 12.6 ± 1.7 12.8 ± 2.5 0.7
PLT (103/ml) 244.4 ± 89.2 268.8 ± 81.2 217.5 ± 91.3 0.02
ESR (mm/1sth) 19 (10–40) 12.6 (12.3–13.4) 14.5 (10–53.8) 0.6
CRP (mg/dl) 2.3 (0.8–5.9) 2.9 (0.8-6.6) 2.2 (0.7–5.5) 0.8
C3 (g/l) 1 (0.8–1.1) 1.1 (0.9–1.2) 0.8 (0.5–1.1) 0.002
C4 (g/l) 0.2 (0.1–0.2) 0.2 (0.2–0.3) 0.1 (0.1–0.2) 0.002
sIL-6 (pg/ml) 12.9 (1.6–20.7) 9.1 (2.6–19.4) 12.9 (6.5–20.7) 0.6
eGRF 80.5 (58.1–113.5) 91 (65.8–113.5) 74.7 (52.7–105.7) 0.3
Proteinuria (mg/l) 0 (0–30) 0 (0–10) 15 (15–50) 0.03
Hematuria 9 (14.3) 5 (15.2) 4 (3.3) 0.6
Lupus nephritis 15 (23.8) 7 (21.2) 8 (26.7) 0.3
Disease activity
SLAM score 5 (3–8) 5 (3.5–8) 5 (5–9) 0.9
Medications
Steroids 55 (87.3) 28 (84.8) 27 (90) 0.4
Duration (years) 6 (1.3–11) 9.5 (3.3–12.8) 4 (0.7–9) 0.02
HCQ 45 (71.4) 25 (75.8) 20 (66.7) 0.3
Duration (years) 6 (0.5–10) 7 (1.6–11) 4 (0.1–6.5) 0.02
IL-6: interleukin-6, F:M: female to male ratio, DD: disease duration, TLC: total leukocytic count, LYM: lymphocytes, Hb: hemoglobin, PLT:
platelets, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, C: complement, sIL-6: serum IL-6, eGFR: estimated glomerular
filtration rate, SLAM: Systemic Lupus Activity Measure, HCQ: hydroxychloroquine.
Low vs. high urinary IL-6. Results are presented as n (%), mean ± SD or median (range). Low urinary IL-6 is <7.3 and high isP7.3 pg/ml).
The eGRF is calculated as ml/min/1.73 m2. Bold values are significant at p< 0.05.
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proteinuria. However, the SLAM score was not related to uri-
nary IL-6. Longer duration of both SLE and therapy with
corticosteroids or HCQ was associated with lower IL-6
(Table 2).
When the subgroups of patients defined based on median
urinary IL-6 were comparatively evaluated, patients with high
IL-6 urinary levels had a shorter SLE duration, lower throm-
bocyte number, C3 and C4 levels, but higher proteinuria. They
were treated for a shorter time with corticosteroids and HCQ.
SLAM score and eGFR were similar in both groups. Notably,
serum IL-6 levels were similar in the two subgroups (Table 1).
In a model of bivariate logistic regression only a lower C4
(r= 0.87, 95% CI 0.79–0.95; p= 0.03) correctly identified
patients with a higher than median urinary IL-6 level in 62%
of cases (r= 0.21; p< 0.001).
As IL-6 urinary but not serum levels were related to some
of the investigated parameters, we supposed that local, intrar-
enal, production of IL-6 could have a contribution. Accord-
ingly, we grouped the patients in respect to the presence of
LN. In the subgroup of patients with active LN (n= 15) uri-
nary IL-6 was negatively correlated with lymphocyte number,
hemoglobin, C3, C4 level (Table 2 and Fig. 1). In regression
analysis, the determinants of urinary IL-6 level were C3, lym-
phocytes number, and the duration of therapy with corticos-
teroids or HCQ, but only C3 had a significant contribution
(Table 3).Please cite this article in press as: Dima A et al. Clinical significance of serum and urin
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.0054. Discussion
In this study, higher urinary not serum IL-6 were related to
indices of SLE activity (lower C3 and C4), mostly in patients
with kidney involvement, pointing to a renal source of IL-6.
Lower IL-6 was also associated with longer duration of
HCQ therapy, supporting an inhibitory action of HCQ on
IL-6 production. Patients in the present study were sub-
grouped into low and high urinary IL-6 based on the median
level (7.3 pg/ml) as reference data on serum or urinary IL-6
levels in SLE patients were not consistent [10,23–27].
Although previous studies concordantly reported higher
IL-6 levels in SLE than in healthy controls, regardless the type
of biological samples assessed, its diagnostic utility is still
uncertain, as data were heterogeneous [7–13]. For instance,
serum determinations of IL-6 levels largely varied from 0.3
to 9.8 pg/ml [10,23–27], such as 3.2 pg/ml in the new onset
active SLE patients, 3.6–4.0 pg/ml in those with renal involve-
ment [26], and 12.9 pg/ml in patients with Jaccoud’s arthropa-
thy [28]. Accordingly, the currently available data do not allow
defining IL-6 cut-off level for SLE activity.
In the present study there was no significant correlation
between serum IL-6 levels and disease activity or flare occur-
rence. The published data are contradictory as some reported
a positive correlation [10,29–31] while others described no rela-
tion [24]. A correlation between serum [32] or urinary [33] IL-6
and the presence of LN has been reported. Consequently, it isary interleukin-6 in systemic lupus erythematosus patients, The Egyptian Rheu-
Table 2 The relationships between urinary IL-6 levels and the
investigated parameters in the total SLE patients and in those
with lupus nephritis.
Parameters r (p) SLE patients
All (n= 63) LN (n= 15)
DD (years) 0.35 (0.01) 0.4 (0.2)
LYM (103/ml) 0.12 (0.3) 0.66 (0.01)
Hb (mg/dl) 0.14 (0.3) 0.67 (0.01)
PLT (103/ml) 0.38 (0.002) 0.33 (0.2)
C3 (g/l) 0.43 (0.001) 0.67 (0.01)
C4 (g/l) 0.46 (<0.001) 0.87 (<0.001)
Proteinuria (mg/l) 0.25 (0.04) 0.28 (0.3)
Steroids (years) 0.39 (0.002) 0.6 (0.02)
HCQ (years) 0.38 (0.003) 0.52 (0.05)
SLAM score 0.048 (0.71) 0.62 (0.01)
SLE: systemic lupus erythematosus, LN: lupus nephritis, IL-6:
interleukin-6, DD: disease duration, LYM: lymphocytes, Hb:
hemoglobin, PLT: platelets, C: complement, HCQ: hydroxy-
chloroquine, SLAM: Systemic Lupus Activity Measure. Bold val-
ues are significant at p< 0.05.
Figure 1 Correlation between urinary IL-6 and C3 levels in SLE
patients.
Table 3 Determinants of urinary IL-6 in patients with lupus
nephritis.
LN patients (n= 15)
R 95% (CI) p
(Constant) (43.7–86.4) 0.001
C3 (mg/dl) 0.54 (0.5 to 0) 0.048
LYM count 0.36 (0.02 to 0) 0.08
Steroids (years) 0.95 (5.5 to 0.2) 0.07
HCQ (years) 0.66 (1.4 to 5.2) 0.21
LN: lupus nephritis, CI: confidence interval, C3: complement factor
3, LYM: lymphocytes, HCQ: hydroxychloroquine. Bold values are
significant at p< 0.05.
4 A. Dima et al.difficult to establish the significance of serum IL-6 in respect to
lupus disease activity. We can only assume that there might be
subgroups of SLE patients with certain clinical features in
which the serum IL-6 kinetics might correlate with disease
activity.
Peterson et al. found no correlation between serum and uri-
nary IL-6 in SLE patients. Nevertheless, they observed that
urinary IL-6 expression correlated with renal impairment as
well as with lupus activity evaluated by SLAM score [10]. Fur-
thermore, high urinary IL-6 levels were found not only in SLE
patients with glomerulonephritis, but also in those with inter-
stitial disease [34]. Even so, other authors did not identifyPlease cite this article in press as: Dima A et al. Clinical significance of serum and urin
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.005urinary IL-6 as a reliable marker for LN [11]. The discordance
between serum and urinary IL-6 levels focused the search for a
renal, local source, of IL-6. IL-6 was found by immunostaining
in the monocyte–macrophage infiltrates in kidney biopsies [35]
and also in the mesangial cells and glomerular immune depos-
its, but not in the normal renal tissue [14]. Activated mono-
cytes may induce IL-6 synthesis in mesangial cells through a
CD40 ligand [15]. It was postulated that IL-6 expression in
mesangial cells may be enhanced by the anti-DNA antibodies
[35].
In our study, there was a significant association of urinary,
not of serum, IL-6 with proteinuria and complement fractions,
but not with SLE activity. Moreover, in patients with LN, IL-6
was inversely correlated with C4 and, in logistic regression, C4
level was the independent determinant of LN. Accordingly, a
particular IL-6 kinetic in the subgroup of SLE patients with
renal involvement, kidney lesions being the main source, can
be assumed. Thus, urinary IL-6 might be a marker of LN
activity.
Even if the HCQ mechanism of action is not understood, its
benefits in SLE are well known [36]. In our data, urinary IL-6
levels were lower in patients with a longer total duration of
therapy with HCQ. This is in line with other reports, where
a decrease in serum and salivary IL-6 [37] as well as a decline
in IFN-a levels [24] was described under HCQ therapy.
Regarding a possible impact of HCQ on IL-6 production, it
was proposed that HCQ might inhibit the production of
IL-6 by T cell and monocyte [38]. More recently, da Silva
et al. demonstrated in vitro that HCQ inhibits the production
of pro inflammatory interleukins and suggested that HCQ
might have an impact on the antigen presentation [39]. Thus,
urinary IL-6 could also be used as a marker for the efficacy
of HCQ therapy.
The presented data should be interpreted with caution, as
longer SLE duration could be related to kidney disease activity
and to the duration of therapy, and both could influence IL-6
urinary levels. One of our study limits was the low number of
patients, especially of those with renal impairment. Moreover,
the renal involvement was defined only on the urine examina-
tion (according to 2012 SLICC criteria); we did not have data
on the renal biopsies of these patients. Even so, we identified
some correlations between urinary IL-6 and renal impairment
in SLE and we observed an interesting relation between the
HCQ treatment and urinary IL-6 expression. Prospective
follow-up of SLE patients is necessary to evaluate the long-
term impact of high IL-6 levels.ary interleukin-6 in systemic lupus erythematosus patients, The Egyptian Rheu-
Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients 55. Conclusion
Urinary IL-6 could be a useful auxiliary parameter to assess
disease activity in the subgroup of SLE patients with renal
involvement as its expression seems more related to a renal
origin. HCQ could act by inhibiting IL-6 production, as lower
urinary IL-6 was observed in patients with longer HCQ ther-
apy duration.
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